Organ support & nutrition

Early trajectories of pulmonary hemodynamics in acute respiratory distress syndrome (ARDS) patients undergoing V-V ECMO: key determinants and prognostic impact

Crit CarePublished Retrospective observational study

Authors' conclusion

Pulmonary hypertension is highly prevalent in ARDS patients on V-V ECMO and reflects underlying disease severity. Early upward trajectories in mPAP, rather than the initial mPAP value, independently predicted higher mortality.

Study context

Population
Adults with ARDS receiving V–V ECMO monitored with a pulmonary artery catheter, tertiary referral center, 2003–2024of 240 consecutive
Participants
225 adults
Outcome
Determinants of mPAP; association of day-1 mPAP and mPAP trajectory over first 5 ECMO days (patient-specific daily slope) with hospital mortality
Methodological detailssingle-centre, tertiary referral center, linear mixed-effects model, logistic regression with adjustment for confounders, Daily hemodynamic, ventilatory and gas exchange data prospectively collected
  • Single-centre
  • Tertiary referral center
  • Linear mixed-effects model
  • Logistic regression with adjustment for confounders
  • Daily hemodynamic, ventilatory and gas exchange data prospectively collected

Main finding

As reported in the abstract

mPAP during ECMO and its association with hospital mortality

Median mean pulmonary artery pressure (mPAP) during ECMO (mmHg) [IQR]

27

23–32

Measurements exceeding 20 mmHg

91%

mPAP trajectory over first 5 days independently associated with mortality, adjusted OR per 1-mmHg/day increase

1.89

95% CI 1.33–2.77p < 0.001

Observational data: associations, not effects.

Original publication

Early trajectories of pulmonary hemodynamics in ARDS patients undergoing V-V ECMO: key determinants and prognostic impact. Crit Care. Published 2 March 2026. doi:10.1186/s13054-026-05855-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.